In patients with atherosclerotic cardiovascular disease, a sodium / glucose cotransporter 2 (SGLT2) inhibitor or a GLP-1 receptor agonist may be recommended because of evidence that these classes of drugs decrease major adverse cardiovascular events (eg, myocardial infarction, stroke) and mortality.